Close Menu

This article has been updated to include companion diagnostic approval information.

NEW YORK – Genentech said on Monday that the US Food and Drug Administration has approved atezolizumab (Tecentriq) as a first-line treatment for metastatic non-small cell lung cancer that expresses PD-L1 in 50 percent or more of tumor cells and has no genetic aberrations in EGFR or ALK.

The FDA also approved the VENTANA PD-L1 SP142 Assay by Ventana Medical Systems as a companion diagnostic device for selecting NSCLC patients for treatment with atezolizumab. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.